Business Wire

Hunton Andrews Kurth Expands Global Privacy and Cybersecurity Practice with Addition of Sarah Pearce in London

Share

Hunton Andrews Kurth LLP continues the expansion of its global privacy and cybersecurity practice with the addition of Sarah Pearce as a partner in the firm’s London office.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907005103/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sarah Pearce joins Hunton Andrews Kurth as a partner focused on privacy and cybersecurity risks and compliance matters in the United Kingdom and European Union (Photo: Hunton Andrews Kurth)

Pearce advises a range of clients in identifying, evaluating, and managing privacy and cybersecurity risks and compliance matters in the United Kingdom and European Union. She has extensive experience developing privacy compliance frameworks to address U.K. and EU General Data Protection Regulation considerations and advises companies in navigating data security incidents and regulatory investigations.

“Sarah brings deep leadership experience and a strong U.K. and European privacy outlook, which will bolster the firm’s offerings to our clients, including U.S. companies operating in the UK and EU,” said Lisa J. Sotto, head of Hunton Andrews Kurth’s global privacy and cybersecurity practice.

Pearce most recently led Paul Hastings LLP’s U.K. and European privacy and cybersecurity practice from the firm’s London and Paris offices, advising companies on data privacy and security issues in the U.K. and across Europe, including the impact of Brexit negotiations and the aftermath of the U.K.’s departure from the EU.

“With Sarah’s experience, we are excited to further strengthen our team’s unique ability to provide clients with seamless, timely and practical advice across jurisdictions,” said privacy and cybersecurity practice partner Aaron P. Simpson.

Pearce is a law graduate of King’s College, London, and Université 1 Panthéon-Sorbonne, Paris and completed her LPC at The University of Law, Guildford.

A leader in its field, Hunton Andrews Kurth’s global privacy and cybersecurity practice helps companies manage data and mitigate risks at every step of the information life cycle. The group advises clients in myriad industry sectors on compliance with international data protection laws, including the GDPR and EU member-state implementations, and U.S. federal and state privacy and information security requirements; the prevention and management of data breaches and cybersecurity incidents, including disputes arising from those events; and the development of corporate data use and privacy policies.

About Hunton Andrews Kurth

With over 900 lawyers in the United States, Asia, Europe and the Middle East, Hunton Andrews Kurth LLP serves clients across a broad range of complex transactional, litigation and regulatory matters. We are known for our strength in the energy, financial services, real estate, and retail and consumer products industries, as well as our considerable experience in more than 100 distinct areas of practice, including privacy and cybersecurity, intellectual property, environmental, and mergers and acquisitions. Visit HuntonAK.com.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gabriel Hedengren, The PR Office
E: ghedengren@theproffice.com
M: +447900198520

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye